SCHEMBL16631187

SCHEMBL16631187

Cc1c[nH]c2nc(=O)c([C@@H]3O[C@H](CO)C(O)[C@@H]3O)cc-2c1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SLC5A2 P31639 8/20 0.44
SYNJ2 O15056 1/20 0.39
SLC5A1 P13866 3/20 0.39
PYGL P06737 3/20 0.38
KDM4E B2RXH2 1/20 0.37
GMNN O75496 1/20 0.37
LMNA P02545 1/20 0.37
MAPT P10636 1/20 0.37
BLM P54132 1/20 0.37
PMP22 Q01453 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
TSHR P16473 1/20 0.37
NFKB1 P19838 1/20 0.37
STAT6 P42226 1/20 0.37
HIF1A Q16665 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16631866 0.86 SLC5A2 (0.44) SLC5A2SLC5A1PYGLKDM4EGMNN
SCHEMBL18080079 0.86 SLC5A2 (0.39) SLC5A2PYGLKDM4EGMNNLMNA
SCHEMBL16631347 0.83 SYNJ2 (0.41) SLC5A2SYNJ2SLC5A1PYGLKDM4E
SCHEMBL18080095 0.82 PYGL (0.43) SLC5A2PYGL
SCHEMBL16631261 0.82 KDM4E (0.40) SLC5A2SYNJ2SLC5A1PYGLKDM4E
SCHEMBL18080214 0.82 KDM4E (0.40) SLC5A2SYNJ2SLC5A1PYGLKDM4E
SCHEMBL16631668 0.81 SLC5A2 (0.40) SLC5A2SYNJ2SLC5A1PYGLKDM4E
SCHEMBL16631576 0.81 KDM4E (0.40) SLC5A2SYNJ2SLC5A1PYGLKDM4E
SCHEMBL16631307 0.81 PYGL (0.47) SLC5A2PYGLKDM4EMAPT
SCHEMBL16631200 0.81 SYNJ2 (0.39) SLC5A2SYNJ2SLC5A1KDM4EGMNN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160264614-A1 POLYNUCLEOTIDE MOLECULES AND USES THEREOF MODERNA THERAPEUTICS, INC. (US) 2016-09-15 US disclosed
US-20160264614-A1 POLYNUCLEOTIDE MOLECULES AND USES THEREOF MODERNA THERAPEUTICS, INC. (US) 2016-09-15 US disclosed
WO-2015051173-A2 POLYNUCLEOTIDE MOLECULES AND USES THEREOF MODERNA THERAPEUTICS, INC (US) 2015-04-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160264614-A1 POLYNUCLEOTIDE MOLECULES AND USES THEREOF POLRMT, POLN, NSUN3 SLC5A2 3235/4885SYNJ2 642/4885SLC5A1 3466/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.